공시 • May 14
IntegraGen SA, Annual General Meeting, May 13, 2026 IntegraGen SA, Annual General Meeting, May 13, 2026. Location: evry France New Risk • Apr 28
New major risk - Negative shareholders equity The company has negative equity. Total equity: -€909k This is considered a major risk. Being in negative equity means that the company's liabilities exceed its assets, meaning it owes more to creditors than it has in owned assets. While this doesn't mean the company is about to collapse, in the long-term, this is unsustainable. The company may have issues meeting financial obligations, is at risk of becoming insolvent and may have difficulty raising capital, especially more debt, if needed. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (14% average weekly change). Negative equity (-€909k). Earnings have declined by 51% per year over the past 5 years. Market cap is less than US$10m (€1.12m market cap, or US$1.31m). Minor Risk Less than 1 year of cash runway based on current free cash flow (-€1.6m). New Risk • Nov 03
New major risk - Revenue and earnings growth Earnings have declined by 30% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings have declined by 30% per year over the past 5 years. Market cap is less than US$10m (€999.7k market cap, or US$1.15m). Board Change • Oct 02
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 6 non-independent directors. Director Francois Fontaine was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Jul 02
IntegraGen SA Not Maintains Revenue Guidance for the Full Year of 2025 IntegraGen SA omits to maintain revenue guidance for the full year of 2025. For the period, the company is exploring all strategic options to improve its situation and expects to reduce cash consumption in the second half of the year through the reduction of operating costs, the launch of services for several existing customers, external sources of financing, a resumption of customer research projects, as well as the expected upturn in customers' research budgets. Given the high level of uncertainty surrounding public research funding, the company is not maintaining its revenue growth forecasts for 2025. 공시 • May 16
IntegraGen SA, Annual General Meeting, Jun 19, 2025 IntegraGen SA, Annual General Meeting, Jun 19, 2025. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France New Risk • May 07
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€4.14m market cap, or US$4.71m). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Share price has been volatile over the past 3 months (7.8% average weekly change). New Risk • Feb 15
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.58m market cap, or US$3.75m). Minor Risk Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). New Risk • Nov 17
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Market cap is less than US$10m (€3.11m market cap, or US$3.27m). Minor Risk Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). New Risk • Sep 10
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of French stocks, typically moving 9.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.4% average weekly change). Market cap is less than US$10m (€3.44m market cap, or US$3.79m). 공시 • May 17
IntegraGen SA, Annual General Meeting, Jun 20, 2024 IntegraGen SA, Annual General Meeting, Jun 20, 2024. Location: genopole campus 1 genavenir 8, 5 rue henri desbrueres, evry France Reported Earnings • May 06
Full year 2023 earnings released Full year 2023 results: Revenue: €12.8m (down 2.9% from FY 2022). Net loss: €171.4k (loss widened €167.9k from FY 2022). 공시 • Jan 17
IntegraGen SA to Report Fiscal Year 2023 Results on Apr 24, 2024 IntegraGen SA announced that they will report fiscal year 2023 results on Apr 24, 2024 New Risk • Oct 25
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of French stocks, typically moving 6.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Market cap is less than US$10m (€6.32m market cap, or US$6.69m). Minor Risk Share price has been volatile over the past 3 months (6.2% average weekly change). Valuation Update With 7 Day Price Move • Jan 02
Investor sentiment improved over the past week After last week's 19% share price gain to €1.43, the stock trades at a trailing P/E ratio of 33x. Average trailing P/E is 12x in the Biotechs industry in France. Total returns to shareholders of 33% over the past three years. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 20
First half 2022 earnings released First half 2022 results: Revenue: €6.76m (up 34% from 1H 2021). Net loss: €141.0k (loss narrowed 66% from 1H 2021). Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 7 non-independent directors. Chief Strategy & Innovation Officer and Director Jean-Pol Detiffe was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Oct 10
First half 2021 earnings released The company reported a soft first half result with weaker earnings and weaker control over costs, although revenues improved. First half 2021 results: Revenue: €5.14m (up 9.2% from 1H 2020). Net loss: €411.0k (down €427.6k from profit in 1H 2020). Breakeven Date Change • Jun 20
Forecast to breakeven in 2021 The analyst covering IntegraGen expects the company to break even for the first time. New forecast suggests the company will make a profit of €300.0k in 2021. Earnings growth of 122% is required to achieve expected profit on schedule. Reported Earnings • Apr 26
Full year 2020 earnings released The company reported a soft full year result with increased losses and weaker control over costs, although revenues improved. Full year 2020 results: Revenue: €9.15m (up 11% from FY 2019). Net loss: €375.0k (loss widened 32% from FY 2019). Is New 90 Day High Low • Nov 16
New 90-day low: €2.12 The company is down 3.0% from its price of €2.18 on 18 August 2020. The French market is up 9.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Biotechs industry, which is up 15% over the same period. Is New 90 Day High Low • Oct 24
New 90-day high: €2.30 The company is up 5.0% from its price of €2.20 on 24 July 2020. The French market is up 1.0% over the last 90 days, indicating the company outperformed over that time. However, it underperformed the Biotechs industry, which is up 13% over the same period. 공시 • Sep 17
OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million. OncoDNA SA signed an agreement to acquire IntegraGen SA (ENXTPA:ALINT) for €14.5 million on July 8, 2020. OncoDNA will acquire all shares of IntegraGen at an offer per share of €2.20. The transaction is structured as a tender offer. The transaction is subject to the approval of the Autorité des Marchés Financiers and applicable regulations to foreign investment control in France. The offer was approved on a unanimous basis by all members of the Board of both companies. As of September 15, 2020, the transaction was approved by AMF. The offer shall be opened at the end of the third quarter of 2020. On September 16, 2020, Oncodna formally launched the tender offer and will be open for acceptances in the next 25 days. ODDO BHF SCA acted as financial advisor, White & Case LLP Avocats-Advocaten and Osborne Clarke BV CVBA acted as legal advisors for OncoDNA. Portzamparc acted as financial advisor, Olivier Grivillers of Crowe HAF acted as fairness opinion provider and Jones Day acted as legal advisor for IntegraGen.